Richard Que
About Richard Que
Richard Que is a Scientist II at Singular Genomics, specializing in CRISPR/Cas9 gene editing technology for biotherapeutic production. He has a Ph.D. in Biomedical Engineering from UC Irvine and has held various research positions at UC San Diego and UC Irvine.
Current Role at Singular Genomics
Richard Que has been employed at Singular Genomics as a Scientist II since 2020. In this role, he applies his expertise in gene editing technologies to advance the company's biotherapeutic production capabilities. His work focuses on the engineering of Chinese Hamster Ovary (CHO) cells, utilizing CRISPR/Cas9 technology to enhance the efficiency and effectiveness of biotherapeutic development.
Previous Experience at UC San Diego
Prior to his current position, Richard Que worked at UC San Diego in various capacities. He served as a Postdoctoral Researcher from 2018 to 2020, where he contributed to research projects in the field of bioengineering. Additionally, he held roles as a Programmer/Analyst I and Assistant III from 2008 to 2010, gaining valuable experience in research support and data analysis.
Education and Expertise in Biomedical Engineering
Richard Que earned his Doctor of Philosophy (Ph.D.) in Biomedical Engineering from UC Irvine, completing his studies from 2010 to 2016. He also obtained a Master of Science (MS) in the same field from 2010 to 2014. His academic background is complemented by a Bachelor of Science (BS) in Bioengineering (Biotechnology) from UC San Diego, which he completed from 2005 to 2009. His education has equipped him with a strong foundation in biotherapeutic production and gene editing technologies.
Research Experience at UC Irvine
At UC Irvine, Richard Que held multiple research positions. He was a Graduate Student Researcher from 2010 to 2017, where he engaged in significant research projects within the biomedical engineering domain. Following this, he worked as a Postdoctoral Researcher from 2017 to 2018, furthering his research expertise and contributing to advancements in gene editing and biotherapeutics.
Specialization in CRISPR/Cas9 Technology
Richard Que specializes in the application of CRISPR/Cas9 gene editing technology for biotherapeutic production. His focus on engineering CHO cells using this technology is aimed at improving the production processes of biotherapeutics, making him a key contributor to advancements in the field.